Document is current

Article History

Received: 21 May 2024

Accepted: 22 July 2024

First Online: 23 August 2024

Conflict of interest

: C. Loehr is a consultant for Penumbra, Phenox, Stryker. L. Defreyne is a consultant for Stryker. L.L. Price is an employee of Stryker and hold Stryker stock. D.S. Liebeskind is a consultant for Cerenovus, Genentech, Medtronic, Rapid Medical, Stryker, and Vesalio. M. Möhlenbruch received research grants from Acandis, Balt, Medtronic, Microvention, Phenox, Stryker* (*industry payments are made to the research fund of the institution), receives payment or honoraria for lectures from Balt, Medtronic, Stryker* (*industry payments are made to the research fund of the institution). R. Gupta serves as Principal Investigator (PI) for the ASSIST Registry (Stryker), PI for the RECCLAIM II Study (Zoll), Clinical Events Committee (CEC) for the MIND Trial (Penumbra), Data Safety Monitoring Board (DSMB) Membrane Study (Cerenovus), ELEVATE Study (Medtronic) consultant and stock options for Vesalio, Rapid Medical. M.‑N. Psychogios: Grants from the Swiss National Science Foundation (SNF) for the DISTAL trial (33IC30_198783), ICARUS (32003B_220118) and TECNO trial (32003B_204977), Grant from Bangerter-Rhyner Stiftung for the DISTAL trial. Unrestricted Grants for the DISTAL trial from Stryker Neurovascular Inc., Phenox GmbH, Penumbra Inc. and Rapid Medical Inc., Sponsor-PI SPINNERS trial (Funded by a Siemens Healthineers AG Grant), Research agreement with Siemens Healthineers AG, Local PI ACT in STROKE, XXXX, EXCELLENT, TENSION, COATING, SELECT‑2, SURF and ESCAPE-NEXT trials. Speaker fees: Stryker Neurovascular Inc., Medtronic Inc., Penumbra Inc., Acandis GmbH, Phenox GmbH, Siemens Healthineers AG. N. Ntoulias, A. Brehm, S. Miralbés, B. Naravetla, A. Spiotta, M. Martínez-Galdámez, R. McTaggart, P. Vega and O.O. Zaidat declare that they have no competing interests.